Page 177 - Materials Chemistry, Second Edition
P. 177

158                         Life Cycle Assessment of Wastewater Treatment


           TABLE 8.1 (CONTINUED)
           Structure of Assessed Pharmaceuticals
                                       Molar Mass   Solubility in
                                            −1
           Drug Family      Drug        (g mol )  Water (mg L )    Reference
                                                          −1
                          Norfloxacin    319.33   1.78 × 10  (at   Yalkowsky and
                                                         5
                                                     25°C)      Dannenfelser (1992)
                          C 16 H 18 FN 3 O 3
                          Flumequine     261.25   1,240 (at 25°C)  Yalkowsky and
                                                                Dannenfelser (1992)
                          C 14 H 12 FNO 3
                          Sarafloxacin   385.36   105 (at 25°C)   Yalkowsky and
                                                                Dannenfelser (1992)
                          C 20 H 17 F 2 N 3 O 3
                         Sulfamethazine   278.33  1,500 (at 29°C)  Herzfeldt and Kümmel
                          C 12 H 14 N 4 O 2 S                       (1983)
                          Sulfathiazole   255.32  373 (at 25°C)   Yalkowsky and
                                                                Dannenfelser (1992)
                          C 9 H 9 N 3 O 2 S 2
                          Sulfapyridine   249.29  268 (at 25°C)   Yalkowsky and
                          C 11 H 11 N 3 O 2 S                   Dannenfelser (1992)
                        Sulfamethoxazole   253.28  610 (at 37°C)  Yalkowsky and
                          C 10 H 11 N 3 O 3 S                   Dannenfelser (1992)
           Lipid          Clofibric acid   214.65  29 (at 25°C)  Pharmacopoeia (2002)
            regulators    C 10 H 11 ClO 3
                         Octyl salicylate   250.33  10,000 (at   Pharmacopoeia (2002)
                                                     25°C)
                           C 15 H 22 O 3
           β-blockers      Atenolol      266.34    13,300 (at   McFarland et al. (2001)
                                                     25°C)
                          C 14 H 22 N 2 O 3
                          Propranolol    259.34   61.7 (at 25°C)  McFarland et al. (2001)
                          C 16 H 21 NO 2
           Estrogens      17β-estradiol   277.41   3.6 (at 27°C)  Yalkowsky and
                                                                Dannenfelser (1992)
                           C 18 H 24 O 2
                        17α-ethinylestradiol
                                         296.40   11.3 (at 27°C)  Yalkowsky and
                           C 20 H 24 O 2
                                                               Dannenfelser (1992)

              The choice of the reactor configuration and design parameters depends on sev-
           eral factors affecting the performance and the activity of the employed organism.
           Developments in the emerging fungal treatment of pharmaceuticals in WWTP effluent
           are spectacular from a technological point of view. However, these biological methods
           still suffer from different limitations and technological gaps and have a long way to go.
           Little is known about the fate of PhACs and biopharmaceuticals in the environment.
           In addition, the occurrence, fate, or activity of transformed compounds and metabo-
           lites (which might be more toxic) in the environment is also not well known. The other
           concern is that the results of fungal treatment practices have often been obtained from
           in vitro sterilized conditions, employing synthetic liquid media and controlled pH and
           temperature; these results might be irrelevant for real wastewater treatment practices,
           in which a community of microorganisms is growing and possibly interfering with the
           fungal treatment, and may not be practical for scaling up systems.
   172   173   174   175   176   177   178   179   180   181   182